Sera Prognostics Reports Q1 2025 Financial Results

Sera Prognostics, Inc. ( (SERA) ) has released its Q1 earnings. Here is a breakdown of the information Sera Prognostics, Inc. presented to its investors.

Sera Prognostics, Inc., headquartered in Salt Lake City, Utah, is a health diagnostics company specializing in precision pregnancy care, focusing on early prediction of preterm birth risk and other pregnancy complications through innovative biomarker tests.

In its first quarter of 2025 earnings report, Sera Prognostics announced a revenue of $38,000, marking an improvement from the previous year’s nil revenue for the same period. The company highlighted its strategic initiatives, including engaging with Medicaid plans for its PreTRM test and preparing for a significant presence at the upcoming ACOG 2025 Annual Clinical & Scientific Meeting.

Key financial metrics for the quarter included total operating expenses of $9.3 million, a slight increase from $9.1 million in the previous year, and a net loss of $8.2 million compared to $8.1 million in the prior-year quarter. Research and development expenses decreased by approximately 9% due to reduced clinical study costs, while selling, general, and administrative expenses rose as the company invested in strategic growth initiatives.

Looking forward, Sera Prognostics remains committed to leveraging the results of its PRIME study to engage with healthcare providers and expand the adoption of its PreTRM test. The company aims to demonstrate the test’s potential in improving healthcare outcomes and reducing costs, particularly in regions heavily impacted by premature births.